Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @ASHClinicalNews
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ASHClinicalNews
-
ASH Clinical News proslijedio/la je Tweet
Well written and detailed article from
@ASHClinicalNews on the costs for treatment of hemophila, including quotes from@CroteauMD.https://www.ashclinicalnews.org/spotlight/feature-articles/high-price-hemophilia/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Toot Your Own Horn: In a review of approximately 6.2 million life sciences articles published between 2002 and 2017, woman researchers were 12.3% less likely than men to frame their work positivelypic.twitter.com/KKwIjWJuFV
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We asked
@CroteauMD, other#hemophilia specialists, and hemophilia treatment center administrators why the price tags for treatment of this rare disease are so uncommonly highhttps://www.ashclinicalnews.org/spotlight/feature-articles/high-price-hemophilia/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The February issue discusses the high price of treating
#hemophilia, debates whether CAR T-cell therapies are worth the costs, and morehttps://www.ashclinicalnews.org/all-issues/february-2020-volume-6-issue-3/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
More than 1/3 of patients with ruxolitinib-refractory
#myelofibrosis benefited from the combination of navitoclax and ruxolitinibhttps://www.ashclinicalnews.org/on-location/ash-annual-meeting/adding-navitoclax-ruxolitinib-ruxolitinib-refractory-myelofibrosis-leads-improvements-spleen-volume-symptom-burden/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
After 3 years of follow-up, ECHELON-1 investigators report that the benefits of brentuximab vedotin are sustained and consistent across risk subgroups in patients with advanced Hodgkin
#lymphomahttps://www.ashclinicalnews.org/news/from-the-blood-journals/written-in-blood/updates-echelon-1-brentuximab-vedotin-provides-durable-efficacy-hodgkin-lymphoma/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Transfusion Confusion: A study in
@JAMA found that for critically ill pediatric patients needing red blood cell transfusions, there was no significant difference in the proportion of patients developing organ dysfunction according to the “freshness” of the blood product usedHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Time-limited frontline therapy with acalabrutinib, venetoclax, and obinutuzumab leads to encouraging rates of complete remission with high rates of undetectable measurable residual disease in chronic lymphocytic
#leukemia (#CLL)https://www.ashclinicalnews.org/on-location/ash-annual-meeting/time-limited-acalabrutinib-combination-encouraging-response-rates-previously-untreated-chronic-lymphocytic-leukemia/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
“These results suggest future
#AML trials may liberalize comorbidity and organ function eligibility criteria, which will likely improve recruitment rates and provide equitable access to investigational products.” –@StatlerA16 from@ClevelandClinichttps://www.ashclinicalnews.org/on-location/ash-annual-meeting/clinical-trials-exclusion-criteria-patients-aml-strict/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Written in
@BloodJournal: In patients with acute myeloid#leukemia (#AML) with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1+ fusion, serial assessment of measurable residual disease can identify people at a high risk for relapse during treatment and follow-uphttps://www.ashclinicalnews.org/news/from-the-blood-journals/written-in-blood/achievement-mrd-negativity-predicts-favorable-prognosis-runx1-runx1t1-aml/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Is Age Just a Number? More older patients with multiple
#myeloma are undergoing transplantation and deriving the same benefit as younger patients, although it has previously been deemed too risky for patients >70 yearspic.twitter.com/uX5p9BtwU2
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
@US_FDA and@ASH_hematology partnered to bring hematologists practical information about newly approved agents during the “ASH-FDA Symposium on New and Late-Breaking Drug Approvals” at#ASH19https://www.ashclinicalnews.org/on-location/ash-annual-meeting/perspectives-2019s-new-hematology-drug-approvals/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Presented by
@End_myeloma from@uabmedicine at#ASH19: Bispecific antibody CC-93269 was reported to have a “manageable” safety profile in patients with heavily pretreated multiple#myeloma, although several patients developed cytokine release syndromehttps://www.ashclinicalnews.org/on-location/ash-annual-meeting/early-phase-trial-suggests-cc-93269-activity-relapsed-refractory-multiple-myeloma/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Correcting Cancer Care Chasms: A report from
@LevineCancer shows that hands-on interventions to improve access to care can help correct racial disparities in#lymphoma outcomes.pic.twitter.com/m2N6TLkzjq
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A Los Angeles jury found that Yescarta from Gilead’s Kite Pharma unit infringed on a patent exclusively licensed from Memorial Sloan Kettering by Bristol-Myers’ Juno Therapeutics divisionhttps://www.ashclinicalnews.org/lymphomas-lymphoid-neoplasia/bristol-myers-wins-752-million-gilead-patent-dispute/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
According to results from the ZUMA-2 trial presented by
@michaelwangmd from@MDAndersonNews at#ASH19, 93% of patients with rel/ref mantle cell#lymphoma (#MCL) responded to treatment with KTE-X19https://www.ashclinicalnews.org/on-location/ash-annual-meeting/kte-x19-car-t-cell-option-mantle-cell-lymphoma/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Older patients who were evaluated in a multidisciplinary team clinic after stem cell transplantation experienced shorter inpatient stays, fewer nursing home admissions, and better early survival rateshttps://www.ashclinicalnews.org/news/from-the-blood-journals/blood-advances/shifting-eligibility-optimization-transplant-older-adults-hematologic-malignancies/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Incomes and Outcomes: Researchers examined clinical trial and socioeconomic data from 1,467 children enrolled in 2 acute myeloid
#leukemia (#AML) trials and found that those from poorer neighborhoods were 2.4x more likely to die during treatment.pic.twitter.com/rw3j2b4B11
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
@US_FDA is struggling to complete inspections of foreign drug manufacturing facilities with only 12 inspectors currently based overseashttps://www.ashclinicalnews.org/news/latest-and-greatest/fdas-overseas-drug-facility-inspections-decline/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Presented by Stephen J. Schuster, MD from
@PennMedicine at#ASH19: Mosunetuzumab led to durable responses in patients with B-cell non-Hodgkin#lymphoma (#NHL), even in those who had disease that was relapsed or refractory to CAR T-cell therapyhttps://www.ashclinicalnews.org/lymphomas-lymphoid-neoplasia/mosunetuzumab-induces-durable-complete-remissions-patients-b-cell-non-hodgkin-lymphoma/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.